Compare CELZ & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELZ | VNRX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.2M |
| IPO Year | 2008 | 2012 |
| Metric | CELZ | VNRX |
|---|---|---|
| Price | $0.94 | $0.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.62 |
| AVG Volume (30 Days) | 240.4K | ★ 1.7M |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.08 | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | $6,000.00 | ★ $1,727,384.00 |
| Revenue This Year | N/A | $57.67 |
| Revenue Next Year | N/A | $240.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40.04 |
| 52 Week Low | $0.62 | $0.13 |
| 52 Week High | $6.25 | $3.26 |
| Indicator | CELZ | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 28.13 |
| Support Level | $0.80 | $0.22 |
| Resistance Level | $2.42 | $0.27 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 41.91 | 24.11 |
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.